

Member FINRA/SIPC

Toll-Free: 866-928-0928 ♦ www.DawsonJames.com ♦ 101 North Federal Highway - Suite 600 ♦ Boca Raton, FL 33432

Soligenix, Inc. (NASDAQ/SNGX)

June 17, 2022

Neutral Rated: We See No Urgency Here

Soligenix Update - 1Q22 Results: The company spent \$4.3M and ended the period with just under \$23M in cash. The share count is up to 42M outstanding. The stock has been unchanged since we last reviewed the company in February 2022 at \$0.61. The company lead product remains delayed “disruptions caused by COVID-19 have resulted in delays by the commercial active pharmaceutical ingredient contract manufacturer, which is now unable to provide the pre-requisite amount of accrued stability data required to file SGX301 (NDA)”. The timeline for anticipated NDA filing with the FDA is now targeting H2-22.

Investment Highlights

The company has cash, but the balance is steadily going lower, and we expect a capital raise next year. The next major event is the filing of the NDA for SGX301 (2H-22). Recall that SGX301 is a therapy to treat CTCL lesions.

The Market is Small. 3,000 US cases annually. We understand that several partnership discussions have stalled (partners may have walked away) as the market is relatively small. In our opinion, the opportunity is not on par with an expensive orphan indication (\$8k annually).

What about Europe? In a letter to shareholders, management states: “We remain steadfast in our plans for partnership in the ex-U.S. markets and continue to pursue discussions with potential partners with similar reputation and expertise in this therapeutic area. We anticipate receiving marketing approval in the U.S. first, and with this approval in hand, we will aggressively pursue marketing authorizations in other key markets worldwide”.

Gone in a “FLASH” (Fluorescent Light Activated Synthetic Hypericin). SGX301 (synthetic hypericin) is a topical ointment applied to CTCL lesions and then activated by safe, visible fluorescent light. This photodynamic therapy has reached its pivotal stage, Phase 3. Approximately 40 additional subjects are being randomized into the trial to maintain the assumption of 90% statistical power for the primary efficacy endpoint. We hold multiple concerns around this product as the technology is new and unproven, and the market size is small.

Valuation: We assign a Neutral rating and have removed our price target. With that said, we do present our market models. We project the model to 2030 and assume the company will continue to operate at a loss.

Risks to our thesis include: (1) clinical trial outcomes; (2) commercial; (3) employee; (4) financial; (5) intellectual property; (6) partnership; and (7) regulatory.

Jason H. Kolbert
Senior Analyst & Managing Director
jkolbert@dawsonjames.com

Current Price \$0.61
Price Target NA



Stock Data			
52-Week Range	\$0.38	-	\$1.32
Shares Outstanding (mil.)	42.9		
Market Capitalization (mil.)	\$26		
Enterprise Value (mil.)	\$19		
Debt to Capital	0%		
Book Value/Share	\$0.72		
Price/Book	2.6		
Average Three Months Trading Volume (K)	99		
Insider Ownership	0.4%		
Institutional Ownership	7.7%		
Short interest (mil.)	1.6%		
Dividend / Yield	\$0.00/0.0%		



Source for the Exhibit at Top: Soligenix

Modeling Assumptions: SGX301

- 1. Prevalence.** There are an estimated 40,000 individuals who have been diagnosed with CTCL worldwide. In the United States, 3,000 new cases are diagnosed each year.
- 2. Clinical and regulatory outcome assumptions.** With positive topline results from the SGX301 Phase 3 study we now expect the company to file the NDA 2H-22 and assume approval and commercialization in 2024.
- 3. Product assumptions.** We assume that a yearly treatment cycle for SGX 301 costs \$8,000. We also predict that the cost of the drug will increase by 1% per year, but this number may be too conservative since the current off-label treatments are priced at \$10,000.
- 4. Probability of Success.** We assign just a 10% risk adjustment to our therapeutic model of SGX301 based on the risks associated with the indications, which have a high failure rate, even in late-stage trials.

Exhibit 1. SGX301 Model

SGX301 (CTCL)																							
SGX301 Revenues Model	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030										
CTCL Prevalence	40,000	42,800	45,796	49,002	51,942	55,058	58,362	61,280	64,344	67,561	70,264	73,074	75,997										
Market Size Growth	7%	7%	7%	6%	6%	6%	5%	5%	5%	4%	4%	4%	3%										
Treated with SGX 301	37,000	39,590	42,361	45,327	48,046	50,929	53,985	56,684	59,518	62,494	64,994	67,594	70,297										
Eligible patients with insurance etc. (75%)	27,750	29,693	31,771	33,995	36,035	38,197	40,489	42,513	44,639	46,871	48,745	50,695	52,723										
Market Penetration	0%	0%	0%	4%	6%	8%	10%	12%	14%	16%	18%	19%	20%										
Treatable Patients	0	0	0	1360	2162	3056	4049	5102	6249	7499	8774	9632	10545										
Average Cost of Therapy	\$8,000	\$8,000	\$8,000	\$8,000	\$8,080	\$8,161	\$8,242	\$8,325	\$8,408	\$8,492	\$8,577	\$8,663	\$8,749										
Price Growth	0%	0%	0%	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%										
Total Sales (\$millions) \$	-	\$	-	\$	11	\$	17	\$	25	\$	33	\$	42	\$	53	\$	64	\$	75	\$	83	\$	92
Risk Adjusted	10%	10%	10%	0%	0%	0%	10%	10%	10%	10%	10%	10%	10%										
Total Sales (US) (\$millions) \$	-	\$	-	\$	-	\$	-	\$	-	\$	3	\$	4	\$	5	\$	6	\$	8	\$	8	\$	9

Source: Dawson James estimates

Risk Analysis

In addition to the typical risks associated with development-stage specialty pharmaceutical companies, potential risks specific to Soligenix are as follows:

Clinical Trial Risk. There can be no assurances that the outcome of the current trials is successful.

Commercial risk. Fluorescent Light Activated Synthetic Hypericin represents a new paradigm in the treatment of CTCL. Adoption may take longer than expected.

Employee risk. Soligenix Inc. has an experienced management team in its president and CEO, CFO, CSO, and CMO. Soligenix plans to bring its proposed products to market in the next two years. The success of the company may depend on the experience, abilities and continued services of its senior officers, sales staff, and key scientific personnel.

Financial risk. Soligenix is not a profitable company. While the company has a cash balance at this time, it's likely that it will need to raise additional capital to continue to fund operations through NDA application and approval. There are no assurances that the company will be able to successfully raise capital and do so on favorable terms.

Intellectual property risk. The company may have to defend its patents and technical know-how, and there can be no assurances that the patents will not be infringed upon or will be held as valid if challenged, and the company may infringe on third parties' patents.

Partnership risks. Soligenix depends on government funding for the public health solutions program. This funding could be canceled at any time.

Regulatory risk. Soligenix must be able to obtain NDA approval before commercial sales of its products can commence in the United States. The timing of these approvals is uncertain. Additionally, the government's biodefense priority might change, affecting the commercial development of RiVax.


Exhibit 2. Income Statement

Soligenix Inc., Inc. Income Statement (\$000)																	
Soligenix Inc.: YE Dec. 31	2018A	2019A	2020A	2021A	1Q22A	2Q22E	3Q22E	4Q22E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
Revenue (\$000)																	
SGX942 (Mucositis) (WW)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
SGX-301	-	-	-	-	-	-	-	-	-	-	3,337	4,247	5,255	6,369	7,526	8,344	9,226
Total Product Sales	-	-	-	-	-	-	-	-	-	-	3,337	4,247	5,255	6,369	7,526	8,344	9,226
% Chg																	
License Revenue	3,965	3,216			50												
Grant Revenue	1,276	1,414			138												
Cost of Grant Revenue	(4,598)	(3,567)															
% Sequential Growth																	
Total Revenues	644	1,063	-	824	188	-	-	-	-	-	3,337	4,247	5,255	6,369	7,526	8,344	9,226
Expenses																	
Cost of Goods Sold & Acquired in Process R&D	-	-	750	(729)	92	-	-	-	92	-	334	425	525	637	753	834	923
COGS % Sales			10%			10%	10%	10%	#DIV/0!	#DIV/0!	10%	10%	10%	10%	10%	10%	10%
Research and development	6,751	8,123	8,912	8,389	1,747	1,747	1,747	1,747	8,557	8,728	8,902	9,081	9,262	9,447	9,636	9,829	10,026
R&D % Revs																	
G&A	2,952	3,481	8,313	4,847	2,552	2,552	2,552	2,552	4,944	5,043	5,144	5,247	5,351	5,459	5,568	5,679	5,793
Stock-based compensation - R&D																	
Stock-based compensation - G&A																	
Non-GAAP Adj																	
Total expenses	9,703	11,604	17,975	13,263	4,391	4,298	4,298	4,298	13,593	13,771	14,380	14,752	15,139	15,543	15,957	16,342	16,741
Oper. Inc. (Loss)	(9,059)	(10,541)	(17,975)	(13,140)	(4,203)	(4,298)	(4,298)	(4,298)	(13,593)	(13,771)	(11,043)	(10,505)	(9,885)	(9,174)	(8,431)	(7,998)	(7,515)
Oper Margin	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM
Interest Income	159	149		421													
Interest expense				(39)	(108)												
Other Income (expense)		426		(862)	(201)												
Change in fair value of warrant liability				204	163												
Pre-tax income	(8,900)	(9,966)	(17,975)	(13,416)	(4,349)	(4,298)	(4,298)	(4,298)	(13,593)	(13,771)	(11,043)	(10,505)	(9,885)	(9,174)	(8,431)	(7,998)	(7,515)
Pretax Margin	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM
Income Tax (Benefit)		611	(810)	864	-	(1,290)	(1,290)	(1,290)	(3,869)	(4,682)	(3,754)	(3,572)	(3,361)	(3,119)	(2,867)	(2,719)	(2,555)
Tax Rate	0%	15%	20%			30%	30%	30%	30%	34%	34%	34%	34%	34%	34%	34%	34%
GAAP Net Income (loss)	(8,900)	(9,356)	(14,168)	(12,550)	(4,349)	(3,009)	(3,009)	(3,009)	(13,375)	(9,089)	(7,288)	(6,933)	(6,524)	(6,055)	(5,564)	(5,279)	(4,960)
GAAP-EPS	(0.79)	(0.49)	(0.55)	(0.31)	(0.10)	(0.07)	(0.07)	(0.07)	(0.31)	(0.20)	(0.15)	(0.14)	(0.13)	(0.11)	(0.10)	(0.09)	(0.08)
Non GAAP EPS (dil)	(0.30)	(0.49)	(0.55)	(0.31)	(0.10)	(0.07)	(0.07)	(0.07)	(0.31)	(0.20)	(0.15)	(0.14)	(0.13)	(0.11)	(0.10)	(0.09)	(0.08)
Wgtd Avg Shrs (Bas) - '000s	13,178	19,377	27,437	40,132	42,920	43,349	43,783	44,221	43,568	45,337	47,178	49,094	51,087	53,161	55,320	57,566	59,904
Wgtd Avg Shrs (Dil) - '000s	13,178	19,377	27,437	40,132	42,920	43,349	43,783	44,221	43,568	45,337	47,178	49,094	51,087	53,161	55,320	57,566	59,904

Source: Dawson James estimates and Company Reports

Important Disclosures:

Price Chart:



Price target and rating changes over the past three years:

- Initiated – Buy – August 5, 2019 – Price Target \$3.00
- Update – Buy – August 14, 2019 – Price Target \$3.00
- Update – Buy – August 28, 2019 – Price Target \$3.00
- Update – Buy – November 20, 2019 – Price Target \$3.00
- Update – Buy – December 4, 2019 – Price Target \$3.00
- Update – Buy – February 12, 2020 – Price Target \$3.00
- Update – Buy – March 31, 2020 – Price Target \$3.00
- Update – Buy – May 1, 2020 – Price Target \$3.00
- Update – Buy – June 24, 2020 – Price Target \$3.00
- Rating Change – Neutral – July 28, 2020 – Price Target \$2.00
- Update – Neutral – September 2, 2020 – Price Target \$2.00
- Update – Neutral – October 22, 2020 – Price Target \$2.00
- Update – Neutral – November 12, 2020 – Price Target NA
- Update – Neutral – December 22, 2020 – Price Target NA
- Update – Neutral – May 11, 2021 – Price Target NA
- Update – Neutral – November 1, 2021 – Price Target NA
- Update – Neutral – February 2, 2022 – Price Target NA
- Update – Neutral – June 17, 2022 – Price Target NA

Dawson James Securities, Inc. (the “Firm”) is a member of the Financial Industry Regulatory Authority (“FINRA”) and the Securities Investor Protection Corporation (“SIPC”).

The Firm does not make a market in the securities of the subject company(s). The Firm has NOT engaged in investment banking relationships with SNGX in the prior twelve months, as a manager or co-manager of a public offering and has NOT received compensation resulting from those relationships. The Firm may seek compensation for investment banking services in the future from the subject company(s). The Firm has NOT received any other compensation from the subject company(s) in the last 12 months for services unrelated to managing or co-managing of a public offering.

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the company(s) in this report and may increase or decrease holdings in the future. As of June 16, 2022, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company(s) of this report. The Firm, its officers, directors, analysts or employees may affect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the company(s) subject to this report. The Firm may affect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad

pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Although the statements in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.

Information about valuation methods and risks can be found in the "VALUATION" and "RISK ANALYSIS" sections of this report.

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request.

Rating Definitions:

- 1) **Buy:** The analyst believes the price of the stock will appreciate and produce a total return of at least 20% over the next 12-18 months;
- 2) **Neutral:** The analyst believes the price of the stock is fairly valued for the next 12-18 months;
- 3) **Sell:** The analyst believes the price of the stock will decline by at least 20% over the next 12-18 months and should be sold.

The following chart reflects the range of current research report ratings for all companies followed by the analysts of the Firm. The chart also reflects the research report ratings relating to those companies for which the Firm has performed investment banking services.

Current as of 16-Jun-22

	Company Coverage		Investment Banking	
Ratings Distribution	# of Companies	% of Total	# of Companies	% of Totals
Market Outperform (Buy)	31	72%	4	13%
Market Perform (Neutral)	12	28%	0	0%
Market Underperform (Sell)	0	0%	0	0%
Total	43	100%	4	9%

Analyst Certification:

The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.